Previous 10 | Next 10 |
Exelixis, Inc. ( EXEL ), a mid-sized pharmaceutical, is a strong buy, forecast to double in the next five years, with potential to do much better than that. Analysis E XEL is intriguing on several counts. First, it came through a simple screen for ((A)) FDA-approved drugs, ((B)) positiv...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Retailers cap off the Q1 earnings season in style as Target (TGT), Best Buy (BBY), ...
̶ ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology ̶ ̶ Exelixis will make upfront payment and contribute research funding for option to in-license at Investigational New Drug (IND) filing ̶ Exelixis, Inc. (Nasdaq: EXE...
̶ Presentations to be webcast on www.exelixis.com ̶ Exelixis, Inc. (Nasdaq: EXEL) today announced that the company will be presenting at the following two investor conferences on Tuesday, May 21, 2019, in New York: UBS Global Healthcare Conference: ...
Quick Take Peloton Therapeutics ( PLTX ) intends to raise $150 million in an IPO of its common stock, per an amended registration statement . The company is advancing a pipeline of small molecule therapeutic candidates for the treatment of kidney cancer and other diseases. PLTX has had ...
-- First commercial sale triggers $20 million milestone payment to Exelixis -- Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) has launched MINNEBRO ® (esaxerenone) tablets as a treatment for patients w...
Peloton Therapeutics, Inc. ( PLTX ) is at an advanced stage of development, which will please many investors. The company expects to start patient enrollment for its Phase 3 clinical trial in the second half of 2019. Additionally, three years ago, competitors were valued at $250-500 million in...
Quick Take Peloton Therapeutics ( PLTX ) has filed to raise gross proceeds of $115 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing small molecule therapeutics for the treatment of cancer and other debilitating diseases. PLTX has earned positi...
Exelixis, Inc. (EXEL) Q1 2019 Earnings Conference Call May 1, 2019 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President-Public Affairs and Investor Relations Mike Morrissey – President and Chief Executive Officer Chris Senner – Chief Finan...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...